From progress to paralysis: bridging the translation gap in digital mental health care?

Inez Myin‐Germeys, Elisa Lievevrouw, Simona Di Folco, Ine Van Hoyweghen, Luca Marelli, Michal Hajdúk, Georgia Koppe, Ulrich Reininghaus, Anita Schick, Iveta Nagyová, Jeroen Weermeijer, Matthias SchwannauerPsychological 2025 · DOI

TL;DR

The European Medical Device Regulation (MDR) was designed to ensure patient safety, but it is inadvertently stifling the digital mental health revolution. This paper argues that the current regulatory framework creates a "translation gap," where rigorous, evidence-based apps are trapped in expensive legal limbo while unregulated "lifestyle" apps dominate the market without clinical validation.

What Problem Does This Paper Address?

With over 1 billion people affected by mental health conditions and a projected global cost of €5.5 trillion by 2030, digital health tools (like smartphone apps for monitoring and intervention) are seen as a vital, scalable solution. However, the authors—members of the EU-funded IMMERSE consortium—argue that the European Medical Device Regulation (MDR) 2017/745 has become a bottleneck.

The core challenge is a "Catch-22": if a researcher develops an app to treat a disease, it is classified as a medical device. This subjects it to rigorous, costly, and slow certification processes that academic grants rarely fund. Meanwhile, commercial "lifestyle" apps for stress or mood bypass these rules entirely by avoiding medical claims, leading to a market flooded with tools that lack a proven scientific basis.

Methods

This paper is a perspective piece and editorial based on the real-world experience of the IMMERSE project (Implementing Mobile MEntal health Recording Strategies for Europe). The authors reflect on the five-year development and implementation of the MoMent app, a digital mental health tool trialed across four European countries. They use this case study to perform a qualitative analysis of the regulatory barriers encountered when trying to move a tool from a clinical trial setting to routine healthcare.

Datasets

Not discussed in the paper. As an editorial/perspective piece, it does not introduce new training or evaluation datasets, though it references the broader IMMERSE project which involved clinical implementation across four countries.

Key Insights and Ideas

The authors identify five specific "paralysis" points caused by the current regulatory environment:

  • The "Lifestyle" Loophole: Companies can avoid the MDR by labeling apps for "stress" or "sleep" as lifestyle tools. This creates a distorted market where clinicians and patients often choose the most available app rather than the most evidence-based one.
  • The Funding Cliff: Research funders typically pay for the science (the trial), but not the "CE-marking" (the legal certification). Without this mark, an app cannot be used outside a study, even if the trial proves it is life-saving.
  • The Update Paradox: Digital tools thrive on iterative updates and agile development. However, the MDR requires a "restart" of the validation process for every "substantial" update. This effectively forces MDR-compliant apps to remain outdated to avoid the cost of re-certification.
  • The Post-Trial Ethical Dilemma: Because of the high cost of CE-marking, researchers are often forced to withdraw a successful tool from participants once a trial ends. This violates the ethical principle of providing post-trial access to beneficial interventions.
  • The "Other Clinical Investigation" Barrier: Under current rules, only apps already registered as medical devices can easily be trialed in certain research contexts. This makes it nearly impossible to scientifically validate existing, popular lifestyle apps to see if they actually work.

Key Results

While the paper is qualitative, it highlights the stark contrast between the scale of the problem and the regulatory friction:

  • Global Burden: Mental health problems affect >1 billion people.
  • Economic Impact: Forecasted costs of €5.5 trillion by 2030.
  • Regulatory Misfit: The authors conclude that the MDR "hinders rather than helps" the implementation of clinical innovations. They argue that the current framework widens the gap between community-based prevention (unregulated) and evidence-based medicine (over-regulated).

Limitations and Future Work

The authors acknowledge that the MDR was created with good intentions—to safeguard patient safety—but argue it lacks the flexibility required for software-as-a-service (SaaS) models.

Proposed Solutions: * Adaptable Frameworks: A call for a regulatory evolution that aligns with the rapid development cycles of digital tools. * Multi-Stakeholder Governance: The creation of an international body (similar to the UK's NICE) to develop best-practice guidelines specifically for digital mental health. * Innovation Pathways: Public services need dedicated pathways to fund the transition from "proven in a trial" to "available for the public," ensuring that the most effective tools—not just the ones with the best legal teams—reach the patients who need them.

Summary updated

Abstract

sponsorship: This work is supported by the H2020 research and innovation program (Grant Agreement No. 945263). (H2020 European Research Council|945263)
BibTeX
@inproceedings{myingermeys2025from,
  author = {Inez Myin‐Germeys and Elisa Lievevrouw and Simona Di Folco and Ine Van Hoyweghen and Luca Marelli and Michal Hajdúk and Georgia Koppe and Ulrich Reininghaus and Anita Schick and Iveta Nagyová and Jeroen Weermeijer and Matthias Schwannauer},
  title = {{From progress to paralysis: bridging the translation gap in digital mental health care?}},
  booktitle = {Psychological},
  year = {2025},
  doi = {10.1017/s0033291725102614},
}
Figure